1. Home
  2. AMRX vs NAMS Comparison

AMRX vs NAMS Comparison

Compare AMRX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMRX
  • NAMS
  • Stock Information
  • Founded
  • AMRX 2002
  • NAMS 2019
  • Country
  • AMRX United States
  • NAMS Netherlands
  • Employees
  • AMRX N/A
  • NAMS N/A
  • Industry
  • AMRX Biotechnology: Pharmaceutical Preparations
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AMRX Health Care
  • NAMS Health Care
  • Exchange
  • AMRX Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • AMRX 2.5B
  • NAMS 2.5B
  • IPO Year
  • AMRX N/A
  • NAMS N/A
  • Fundamental
  • Price
  • AMRX $8.07
  • NAMS $23.98
  • Analyst Decision
  • AMRX Strong Buy
  • NAMS Strong Buy
  • Analyst Count
  • AMRX 4
  • NAMS 9
  • Target Price
  • AMRX $11.50
  • NAMS $41.11
  • AVG Volume (30 Days)
  • AMRX 1.5M
  • NAMS 848.8K
  • Earning Date
  • AMRX 08-05-2025
  • NAMS 08-06-2025
  • Dividend Yield
  • AMRX N/A
  • NAMS N/A
  • EPS Growth
  • AMRX N/A
  • NAMS N/A
  • EPS
  • AMRX N/A
  • NAMS N/A
  • Revenue
  • AMRX $2,830,186,000.00
  • NAMS $47,140,000.00
  • Revenue This Year
  • AMRX $9.95
  • NAMS N/A
  • Revenue Next Year
  • AMRX $8.14
  • NAMS N/A
  • P/E Ratio
  • AMRX N/A
  • NAMS N/A
  • Revenue Growth
  • AMRX 13.42
  • NAMS 586.97
  • 52 Week Low
  • AMRX $6.50
  • NAMS $14.06
  • 52 Week High
  • AMRX $9.48
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • AMRX 49.92
  • NAMS 71.31
  • Support Level
  • AMRX $7.79
  • NAMS $22.00
  • Resistance Level
  • AMRX $8.48
  • NAMS $23.04
  • Average True Range (ATR)
  • AMRX 0.20
  • NAMS 1.19
  • MACD
  • AMRX -0.06
  • NAMS 0.30
  • Stochastic Oscillator
  • AMRX 37.84
  • NAMS 86.42

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: